Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary)
- Indications Mouth neoplasm; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Privo Technologies
- 25 Jun 2018 Planned End Date changed from 31 Dec 2019 to 30 Apr 2020.
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.
- 23 Apr 2018 New trial record